Janssen secures win in cancer drug royalties dispute
Belgian pharmaceuticals company Janssen has defeated a claim brought by a Danish biotech company over royalties due for a blood cancer treatment.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now